Jun 16, 2020
CardioFocus® Announces Initial Commercial Procedures Following US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation
Feb 04, 2020
CardioFocus Announces U.S. FDA PMA Supplement Submission For The Breakthrough HeartLight X3 Endoscopic Ablation System
Oct 29, 2019
CardioFocus® Treats First Patients With HeartLight® Endoscopic Ablation System In France
Jun 18, 2019
CardioFocus Launches 100th HeartLight® Center Worldwide
Mar 25, 2019
CardioFocus Announces European CE Mark Approval Of Breakthrough HeartLight® X3 System For The Treatment Of Atrial Fibrillation
Nov 29, 2018
CardioFocus Completes Enrollment In HeartLight® X3 Trial
Jun 22, 2018
GPB Capital Enters into $21 Million Debt Investment in CardioFocus®
May 09, 2018
CardioFocus Announces Successful Live Case Featuring HeartLight® X3 System
May 07, 2018
CardioFocus® Announces FDA Approval Of The Next-Generation HeartLight® Excalibur Balloon(TM) Designed For The Treatment Of Paroxysmal Atrial Fibrillation*
Feb 26, 2018
CardioFocus Announces Intiation of HeartLight® X3 Clinical Evaluation
Jan 09, 2018
CardioFocus® Announces Expanded Partnership With Japan Lifeline
Nov 29, 2017
CardioFocus® Completes Successful Controlled U.S. Commercial Launch of the HeartLight® System
Sep 27, 2017
CardioFocus® Announces European CE Mark Approval Of The Next-Generation HeartLight® Excalibur Balloon(TM) Designed For The Treatment Of Atrial Fibrillation
Jul 31, 2017
CardioFocus® Receives Approval For HeartLight® Endoscopic Ablation System From The Japanese Ministry Of Health, Labour And Welfare